to treat a range of emerging multidrug-resistant bacterial infections in animals (Schwarz, Loeffler, & Kadlec, 2017) . Furthermore, in the interest of proper antimicrobial stewardship, these novel treatments should ideally not represent classes of drug utilized in human medicine, nor should they impart cross-resistance to critically important human drugs. This is particularly important when considering the need for novel antimicrobials for treating bacterial pathogens in production animals, such as those responsible for bovine mastitis.
The high culling rates, production losses, and associated veterinary interventions associated with bovine mastitis have a significant economic impact on dairy industries. For example, in the United States alone, the National Mastitis Council has estimated that mastitis costs the dairy industry $1.5-2.0 billion each year (Middleton et al., 2014) . Treatment of Gram-positive bacterial infections continues to be particularly challenging for dairy farmers. This is particularly true for Staphylococcus spp. and Streptococcus spp., including Staphylococcus aureus, coagulase-negative staphylococci and Streptococcus uberis, which are identified as the causative pathogens in a majority of bovine mastitis cases caused by Gram-positive bacteria (Petrovski, Williamson, Lopez-Villalobos, Parkinson, & Tucker, 2011; Thomas et al., 2015; Zadoks, Middleton, McDougall, Katholm, & Schukken, 2011) .
Staphylococcus aureus is a particularly challenging pathogen in cases of bovine mastitis as it is has a number of virulence factors that prevent effective treatment. Biofilm formation and intracellular penetration are two key factors that facilitate pathogenesis and persistence in this species (da Costa Krewer et al., 2015; Oliviera et al., 2006) . Many antimicrobial preparations available for the treatment of bovine mastitis have limited tissue and intracellular penetration resulting in poor treatment responses (Blowey & Edmondson, 2010) .
Furthermore, the global emergence of methicillin-resistant strains is an additional limiting factor in the treatment of S. aureus mastitis as beta-lactams represent the largest class of antimicrobial agents used for treating bovine mastitis (Holmes & Zadoks, 2011) .
Methicillin-resistant S. aureus (MRSA) is becoming an important cause of lost productivity in dairy cattle that is spreading worldwide with implications to human health, as livestock-associated MRSA strains, such as ST398, are considered to be zooanthroponotic (Gianneechini, Concha, & Franklin, 2002; Holmes & Zadoks, 2011; Myllys et al., 1998; Zadoks et al., 2011) . As livestock−associated MRSA strains are resistant to all beta-lactam antimicrobial treatments, new classes of antimicrobial agents with differing mechanisms of action are urgently required. Despite this need, no new antimicrobials have been approved for mastitis therapy since 2006 (Ruegg, 2014) .
The carboxylic polyether ionophores are a group of antimicrobial agents that are currently used extensively in ruminants and poultry.
Ionophores have a novel mode of action compared to other mastitis treatments and do not promote cross-resistance to classes of antimicrobials of medical significance (Russell & Houlihan, 2003) .
Ionophores have in vitro activity against Gram-positive bacteria, including staphylococci, and oral administration of lasalocid and monensin in feed has reduced the incidence of mastitis in lactating dairy cows (Butaye, Devriese, & Haesebrouck, 2003; Duffield, Rabiee, & Lean, 2008; Kevin, Meujo, & Hamann, 2009; McDougall, Young, & Anniss, 2004; Stefanska, Stepien, Huczynski, & Tyski, 2015) . Furthermore, we have previously shown that lasalocid, when formulated as an intramammary antimicrobial agent, exhibited a high cure rate in treating experimentally-induced bovine mastitis caused by Str. uberis with acceptable safety in treated cows (Wang et al., 2015) .
Repurposing ionophores for a continued veterinary only application would offer a potential solution to the need for novel mastitis treatments while maintaining proper antimicrobial stewardship. The objective of this study was therefore to undertake an in vitro comparison of four cationic polyether ionophores: lasalocid, monensin, narasin and salinomycin, as antimicrobial agents for Gram-positive bovine mastitis pathogens. Our hypothesis was that the ionophores as a group would show in vitro efficacy against both planktonic bacteria and biofilms, and acceptable in vitro cytotoxicity against relevant mammalian cell lines.
| MATERIAL S AND ME THODS

| Bacterial isolates
Bacterial isolates used in this study were obtained from clinical cases of bovine mastitis within Australia. Milk samples from high somatic cell count cows were collected aseptically by the diagnosing veterinarian or the dairy manager, and submitted to veterinary diagnostic laboratories for culture and susceptibility testing. Milk samples were grown on Columbia agar supplemented with 5% defibrinated sheep blood to isolate and characterize the causative pathogen. Standard biochemical testing procedures and other phenotypic tests were applied to determine the identity of the isolate to species level and identities were confirmed prior to MIC testing using 16S rRNA gene sequencing or MALDI-TOF mass spectrometry (Bruker, Australia) according to the manufacturer's protocol for bacterial identification (Markey, Cullinane, Leonard, Maguire, & Archambault, 2013; Milinovich et al., 2006 Institute, 2013; Groves et al., 2016) . A breakdown of the isolates collected is shown in Table 1 . Two ATCC quality control strains were also used during testing: S. aureus ATCC 29213 and Streptococcus pneumoniae ATCC 49619. All isolates were stored at −80°C in brain heart infusion broth with 20% glycerol (vol/vol) until required. 
| Antimicrobial agents
| Antimicrobial susceptibility testing
Minimum inhibitory concentrations (MIC) were determined following the CLSI antimicrobial susceptibility testing guidelines using the broth dilution method as described (Clinical & Laboratory Standards Institute, 2013 
| Bactericidal activity testing
Minimum bactericidal concentrations (MBC) were determined by spot plating all concentrations from the MIC microtiter plate that contained no visual growth in accordance with CLSI guidelines (Clinical & Laboratory Standards Institute, 1999) . In brief, 10 μl was removed from each well and plated onto Sheep Blood Agar in duplicate and allowed to dry. Plates were incubated aerobically at 37°C for 24 hr and then visually assessed for growth. MBCs were defined as the lowest concentration with 99.95% reduction in viable cell counts.
Time-kill kinetics assays were undertaken to confirm MBC results using lasalocid as the representative ionophore for the class.
Kill kinetics were determined at 1×, 4× and 8× MIC using S. aureus Institute, 1999). Viable counts were used to calculate log 10 mean (CFU/ml) ± SEM.
| Erythrocyte haemolysis assay
Haemolysis assays were performed in 96-well microtiter plates with U-shaped wells. Erythrocytes were harvested from whole ovine blood (Thermo Fisher Scientific, Australia) by centrifugation at 2,000 g for 10 min at 20°C. Cells were washed three times with at 37°C for 1 hr and then centrifuged at 2,000 g for 5 min at 20°C.
100 μl of supernatant was transferred to a new 96-well microtiter plate and the absorbance measured at 540 nm. Haemolysis was expressed as a percentage of ultrapure water induced haemolysis.
| In vitro cytotoxicity
In vitro cytotoxicity assays were carried out on lasalocid, monensin, 
| Minimum biofilm eradication concentration testing
Biofilm susceptibility testing was performed in the minimum biofilm eradication concentration (MBEC)™ biofilm assay (MBEC Biofilm Inoculator, Innovotech, Edmonton, Canada) using a representative strain of S. aureus (ATCC 29213). Biofilm formation on the device was established by inoculating the device with a standardized microbial inoculum (1 × 10 5 CFU/ml) and the inoculated device was placed on a rocking platform at 37°C (Select BioProducts, Model SBS300-2, New Jersey, United States), which allows a shear force to be created forming equivalent biofilms on all pegs. Biofilms were exposed to an antimicrobial challenge plate prepared as for MIC testing and incubated at 37°C for 24 hr. Following antimicrobial challenge, the biofilms from all pegs were disrupted via sonication (Soniclean, Model 160TD, Australia). Biofilm susceptibility to antimicrobial agents was assessed quantitatively by determinations of survival using viable cell counts to determine colony forming units (CFU) as previously described (Ceri et al., 1999; Harrison et al., 2010) . Viable counts were then expressed as a percentage of the mean CFU of growth controls. Statistical analysis was performed using the nonparametric Kruskal-Wallis test followed by Dunn's multiple comparison test, using GraphPad Prism v7 software.
| RE SULTS
| MIC values of polyether ionophores against bovine mastitis staphylococci, including methicillinresistant strains
All four polyether ionophores demonstrated in vitro antimicrobial activity against bovine mastitis staphylococci on the basis of MIC testing (Table 2 ). For S. aureus isolates (n = 39), narasin was active at the lower concentrations compared to the other ionophores (MIC 50 = 0.5 μg/ml; MIC 90 = 1 μg/ml; Range = 0.25-1 μg/ml), followed by lasalocid and salinomycin (MIC 50 = 1 μg/ml; MIC 90 = 1 μg/ ml; Range = 0.5-2 μg/ml), and monensin (MIC 50 = 2 μg/ml;
MIC 90 = 8 μg/ml; Range = 1-16 μg/ml). Similar susceptibility profiles and MIC ranges were also determined for coagulase-negative staphylococci ( 
| MIC values of polyether ionophores against bovine mastitis streptococci
Cationic ionophores inhibited the growth of the three major species of bovine mastitis streptococci at MICs that were lower than those obtained for bovine mastitis staphylococci (Table 2) . Reductions in MIC were observed to be more uniform and consistent for narasin, with over 50% of bovine mastitis streptococci isolates exhib- 
| MBC values and time-kill kinetics assays of polyether ionophores against Gram-positive bovine mastitis pathogens
MBC values for all four ionophores against all the isolates tested are shown in Table 3 . MBC values were lowest for narasin (MBC 50 = 8 μg/ ml; MBC 90 > 32 μg/ml, MBC Range = 0.5 to >32 μg/ml), while la- and 8× MIC) to which bacterial cells were exposed.
| Cytotoxicity assays
IC 50 values varied greatly between ionophores depending on the cell line (hepatic, fibroblast, kidney and mammary cell lines; Table 4 ). F I G U R E 1 Viable counts (CFU/ml) of Staphylococcus aureus ATCC 49775 (MIC 1 μg/ml; MBC >32 μg/ml) over a 24 hr period with exposure to lasalocid at 1×, 4× and 8× MIC compared to a growth control. Data is presented as log 10 mean (CFU/ml) ± SEM whereas monensin showed no cytotoxicity for three cell lines at the highest concentration tested.
One-hour exposure of a 2% erythrocyte suspension to the four cationic ionophores resulted in lysis at concentrations greater than 4 μg/ml for salinomycin, lasalocid and narasin (Figure 2 ). Of these compounds, the greatest amount of lysis was observed for narasin, with more than 40% lysis at concentrations greater than 8 μg/ml.
Salinomycin and lasalocid had similar levels of lysis after 1 hr but no lysis was observed at any concentration for monensin or chloramphenicol after 1 hr.
| Minimum biofilm eradication concentration testing
Preformed ATCC 29213 (S. aureus) biofilms were tested against ionophores to determine activity ( Figure 3 ). F I G U R E 2 Percentage (%) of haemolysis obtained from exposing a 2% sheep erythrocyte solution to various concentrations of polyether ionophores for 1 hr compared to a chloramphenicol control F I G U R E 3 Viable cell counts of preformed Staphylococcus aureus biofilms after exposure to (a) Lasalocid, (b) Monensin, (c) Narasin or (d) Salinomycin. All data shown are mean percentages of growth compared to untreated biofilms ± SEM. Groups that are statistically different from the control are denoted with an asterisk (*) monensin 2-32 μg/ml and narasin at 0.5, 1, 4 and 16 μg/ml. A > 50% reduction in viable cell counts was also observed for salinomycin at concentrations ≥8 μg/ml. However, no ionophores examined in this study completely eliminated viable cells from the biofilm; therefore, a minimum biofilm eradication concentration was not identified.
| D ISCUSS I ON
The repurposing of drugs as therapeutics against antimicrobialresistant infections is one rapid and cost-effective solution to the lack of novel antimicrobial agents in the development pipeline, particularly in the animal health field. The aim of this study was to evaluate the potential of four polyether ionophores, lasalocid, monensin, narasin and salinomycin, to be developed as effective Yoo et al., 2007) , this study is the first to clearly demonstrate that polyether ionophores also have activity against bovine-derived methicillin-resistant staphylococci.
Similar to previous studies in other groups of bacteria, the antimicrobial activity of the polyether ionophores was shown to be bacteriostatic for the majority of mastitis pathogens (Nagaraja & Taylor, 1987) . As antiporters, ionophores prevent bacterial replication by disrupting concentration gradients of protons and metal ions across bacterial membranes (Russell & Houlihan, 2003) . However, ionophores are susceptible to pH-dependent ionization and so activity may be improved in a more acidic environment, particularly for lasalocid and salinomycin, which have pKa values lower than the pH of the media used for in vitro testing (Lagas et al., 2008; Russell & Houlihan, 2003) . Despite this, some bactericidal activity was seen most prominently for narasin, which was apparent from the MBC 50 values (8 μg/ml). However, all four ionophores exhibited a wide range of MBC values across the range of isolates tested. While time-kill kinetics assays confirmed bacteriostatic activity for lasalocid and did not suggest concentration-dependent bactericidal activity against the S. aureus ATCC control strain, MBC testing results suggest that ionophore bactericidal activity could be strain-dependent.
As ionophores can translocate ions across mammalian cell membranes, mammalian cell cytotoxicity was also compared. This intrinsic characteristic of ionophores potentially reduces their selective toxicity, and is an important alert for cautious product development.
Whilst our results confirmed the susceptibility of red blood cells to lysis at relatively low ionophore concentrations, they also indicated that all the ionophores, with the possible exception of lasalocid, had important margins of safety between concentrations active against mastitis pathogens and cytotoxic concentrations, as measured by the selectivity index (SI). In an interesting manner, IC 50 and SI values were highest for all the ionophores when tested against mammary carcinoma cells (MCF-7). While these results were determined for a human cell line and host tolerance of ionophores is highly species-specific, it has been widely demonstrated that cattle are amongst the most ionophore-tolerant livestock species, suggesting that a high therapeutic margin of safety may be a reasonable expectation following administration by the intramammary route in cattle (Russell & Houlihan, 2003 values across all the mammalian cells tested with the exception of human fibroblasts and monensin also produced no erythrocyte lysis at concentrations ≤128 μg/ml after a 1-hr exposure. Cytotoxicity testing results suggest that of the four ionophores tested, lasalocid had the lowest IC50 values and this was consistent with the observations of other studies conducted using HepG2 cells (Cybulski, Radko, & Rzeski, 2015; Radko, Cybulski, & Rzeski, 2013) . In our previous work, lasalocid formulated as an intramammary suspension was successfully able to treat experimentally-induced S. uberis mastitis in lactating dairy cows without causing any untoward negative effects (Wang et al., 2015) .
Our current in vitro results confirm that salinomycin, narasin and monensin may have higher selective toxicity indices.
Preliminary evaluation of antibiofilm activity suggests that ionophores exhibit some activity against staphylococcal biofilms. The number of viable cells in biofilms were significantly reduced after 24-hr exposure to low ionophore concentrations. Salinomycin showed the most efficacy against biofilms with a reduction of at least 50% CFU/ml at concentrations greater than or equal to 8 μg/ml. These results are consistent with a previous study conducted on the tolerance of Clostridium perfringens biofilms to monensin, narasin and salinomycin at 4, 1 and 2 μg/ml, respectively (Charlebois, Jacques, & Archambault, 2014 suggest that the efficacy of the ionophores tested against these biofilms was strain-and time-dependent, with viability decreasing with prolonged exposure (Charlebois et al., 2014) . In addition to this, it is well recognized that biofilm tolerance to antimicrobial agents is multi-factorial with a combination of metabolic, physical and adaptive mechanisms, and factors independent of biofilm formation such as conventional resistance (Bjarnsholt, Ciofu, Molin, Givskov, & Høiby, 2013) . Therefore, further research on the exact mechanism of the antibiofilm activity of these ionophores could determine if prolonged exposure or synergistic drug combinations would further increase this activity.
In conclusion, the results of the present study indicate that all four ionophores: lasalocid, monensin, narasin and salinomycin have the potential to be developed as treatments for bovine mastitis as each demonstrated bacteriostatic antimicrobial activity in vitro against a range of Gram-positive mastitis pathogens. Similar to that a reduction in biofilm viability was observed with exposure to ionophores at a range of concentrations but further investigation into the mechanism of this activity is required to optimize antibiofilm activity. Whilst, the results of the present study indicate that all four ionophores tested meet important early development criteria for microbiological potency, spectrum of activity and safety, some differences in selective toxicity were apparent from the comparison of in vitro MIC/MBC and cell cytotoxicity data. Ionophores may therefore be promising leads to meet the growing need for animalspecific antimicrobial agents for the treatment of bovine mastitis with a novel mode of action, unaffected by emerging resistances.
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